Compare RXT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXT | MGNX |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.0M | 115.8M |
| IPO Year | 2020 | 2013 |
| Metric | RXT | MGNX |
|---|---|---|
| Price | $1.92 | $3.34 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $1.71 | ★ $3.40 |
| AVG Volume (30 Days) | ★ 47.9M | 1.2M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,685,700,000.00 | $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $0.99 |
| 52 Week High | $2.74 | $3.50 |
| Indicator | RXT | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 87.97 |
| Support Level | $1.13 | $1.42 |
| Resistance Level | $2.74 | N/A |
| Average True Range (ATR) | 0.43 | 0.18 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 43.40 | 91.34 |
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.